Abstracts tagged "Biomarkers"

Abstract Number: 222 • 2014 ACR/ARHP Annual Meeting
OA Phenotypes Rather Than Disease Stage Drive Structural Progression – Identification of Structural Progressors from 2 Phase III Randomized Clinical studies with Symptomatic Knee OA
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Asger Bihlet³, Peter Alexandersen⁴, Inger Byrjalsen³, Bente J. Riis³ and Claus Christiansen³, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Center for Clinical and Basic Research, Vejle, Denmark
Background/Purpose: Osteoarthritis (OA) is a heterogeneous disorder, with several possible drivers of disease progression. Up to 50% of OA patients do not structurally progress, emphasizing…
Abstract Number: 2147 • 2014 ACR/ARHP Annual Meeting
Automatically Extracted Quantitative Biomarkers for Assessing Connective Tissue Disease Using Nailfold Capillaroscopy
Michael Berks¹, Graham Dinsdale², Andrea Murray², Tonia Moore³, Chris Taylor¹ and Ariane Herrick², ¹Centre for Imaging Sciences, University of Manchester, Institute of Population Health, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³Salford Royal Hospital NHS Foundation Trust, Salford, United Kingdom
Background/Purpose Videomicroscopy can capture high-magnification images of nailfold capillaries, allowing non-invasive assessment of microvasculature change indicative of connective tissue disease. Whilst images may be qualitatively…
Abstract Number: 1631 • 2014 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products and Their Relationship to Disease Activity and Quality of Life Measures in Systemic Lupus Erythematosus
Richard Furie¹, Jill P. Buyon², R. Ramsey-Goldman³, Chaim Putterman⁴, Kenneth Kalunian⁵, Tyler O'Malley⁶, John Conklin⁷, Derren Barken⁸ and Thierry Dervieux⁹, ¹Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁸Exagen Diagnostics, Inc., Vista, CA, ⁹rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: To assess the association between cell bound complement activation products (CBCAPS) and measures of disease activity and quality of life in systemic lupus erythematosus…
Abstract Number: 1135 • 2014 ACR/ARHP Annual Meeting
Genes Involved in Cartilage Synthesis and Risk to Knee Osteoarthritis
Abhishek Mishra Sr., Rajeshwar Srivastava II, Divya Sanghi III, Ajai Singh IV and Devendra Parmar V, Deptt of Orthopaedic Surgery, King George's Medical University,, Lucknow, India
Background/Purpose Osteoarthritis (OA), characterized by gradual loss of articular cartilage in the joint, is a leading cause of disability among the elderly people. Though the…
Abstract Number: 628 • 2014 ACR/ARHP Annual Meeting
The Predictive Value of Cardiovascular and Metabolic Biomarkers for Progression of Atherosclerosis in Psoriatic Disease
Lihi Eder¹, Fatima Abji¹, Cheryl Rosen², Vinod Chandran¹ and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose The pathophysiologic mechanisms underlying the accelerated atherosclerosis in patients with psoriatic disease (PsD) are unknown. We aimed to investigate candidate pathways involved in this…
Abstract Number: 137 • 2014 ACR/ARHP Annual Meeting
Evaluation of Metalloproteinase-3 As a Soluble Biomarker of Synovitis Using Weighted Joint Counts Assessed Clinically and on Ultrasound Imaging
Agata Burska^1,2, Elizabeth Hensor^2,3, Jackie L. Nam³, Lukasz Kozera⁴, Richard J. Wakefield³, Paul Emery³ and Ann W Morgan⁵, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., Leeds, United Kingdom, ²joint first authorship, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Faculty of Pharmacy and Laboratory Diagnostics, Wroclaw Medical University, Wroclaw, Poland, Wroclaw, Poland, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom
Background/Purpose: Synovial inflammation is known to play a central role in articular cartilage degradation in rheumatoid arthritis (RA); it could be a passive marker of…
Abstract Number: 2862 • 2013 ACR/ARHP Annual Meeting
Autoantigen Microarray Analysis Of Sera From New-Onset Pediatric Systemic Lupus Erythematosus Patients: A Distinct Autoantibody Profile Associated With Class III/IV Lupus Nephritis
Imelda Balboni¹, David Haddon², Vivian Diep², Cindy Limb² and Paul Utz², ¹Pediatrics, Stanford University School of Medicine, Palo Alto, CA, ²Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease characterized by the production of autoantibodies directed against highly-conserved nuclear antigens. 15-20% of SLE…
Abstract Number: 2189 • 2013 ACR/ARHP Annual Meeting
TLR 4 Endogenous Ligand MRP8/14 Levels in Enthesitis Related Arthritis (ERA) and Its Association With Disease Activity and TLR 4 Expression
Amita Aggarwal¹, Mujeeb Rahman¹, Arpita Myles², Priyanka Gaur² and Ramnath Misra¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Enthesitis related arthritis (ERA) is an inflammatory disease of childhood that lacks autoreactive T and B cells. We have previously shown that surface expressed…
Abstract Number: 1716 • 2013 ACR/ARHP Annual Meeting
Childhood-Onset Systemic Lupus Erythematosus With Clinical Neurocognitive Dysfunction Have Lower Nodal Density and Connectivity On Diffusion Tensor Imaging
Jordan T. Jones¹, Mark DiFrancesco², Ahmad I. Zaal¹, Marisa S. Klein-Gitelman³, Darren Gitelman⁴, Jun Ying⁵ and Hermine Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Children's Memorial Hospital, Chicago, IL, ⁴Neurology, Northwestern University, Chicago, IL, ⁵Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH
Background/Purpose: Neurocognitive dysfunction (NCD) is common in childhood-onset systemic lupus erythematosus (cSLE), and often difficult to detect with current resources. Diffusion tensor imaging (DTI) is…
Abstract Number: 879 • 2013 ACR/ARHP Annual Meeting
Serological Biomarkers Of Specific Mode Of Action For Early Identification Of Rheumatoid Arthritis Patients Who Respond To Anti-IL6 Or Anti-TNF Treatment
Anne C. Bay-Jensen¹, Natasja Stæhr Gudman², Anne Sofie Siebuhr¹, Claus Christiansen³ and Morten Asser Karsdal², ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized debilitating joint destruction, if not treated aggressively in the patient in most need of treatment. …
Abstract Number: L19 • 2013 ACR/ARHP Annual Meeting
Kellgren-Lawrence Grade (KL) 0 Vs. KL 1 Knees Differ in Their MRI Predictors of Subsequent Radiographic Osteoarthritis
C.Kent Kwoh¹, Ali Guermazi², Tomoko Fujii³, Robert M. Boudreau³, Michael Hannon⁴, Jason Grago⁴, David Hunter⁵, Felix Eckstein⁶ and Frank Roemer⁷, ¹Department of Medicine, The University of Arizona Arthritis Center, Tucson, AZ, ²Radiology, Boston University School of Medicine, Boston, MA, ³Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵University of Sydney, Sydney, Australia, ⁶Paracelsus Medical University, Salzburg, Austria, ⁷Klinikum Augsburg, Augsburg, Germany
Background/Purpose: Kellgren-Lawrence grade (KL) 1, defined by a questionable osteophyte and/or doubtful joint space narrowing, is thought to be an intermediate stage from non-OA (i.e.,…
Abstract Number: 2865 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profiles Of Fibroblast-Like Synoviocytes In Early Stage Of Oligoarticular Juvenile Idiopathic Arthritis Are Different In Extended Versus Persistent Course
AnneMarie C. Brescia¹, Megan M. Simonds², Suzanne M. McCahan², Paul T. Fawcett² and Carlos D. Rose¹, ¹Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ²Nemours Research, Nemours/AI duPont Hospital for Children, Wilmington, DE
Background/Purpose: Our goal is the identification of informative synovial biomarkers to predict persistent vs extended course in oligoarticular JIA patients. Methods: Stored remnant synovial fluid…
Abstract Number: 2071 • 2013 ACR/ARHP Annual Meeting
Adipokines Contribute To The Inflammatory Response In Adult and Juvenile Myositis
Molly S. Hein¹, Cynthia S. Crowson², Helen Khun², Consuelo Lopez de Padilla³, Erik J. Peterson⁴, Emily Baechler⁵ and Ann M. Reed¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ⁴Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ⁵Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: Recently adipokines have been implicated for their role in regulating immune and inflammatory responses in autoimmune disease. To test the hypothesis that adipokines are…
Abstract Number: 1609 • 2013 ACR/ARHP Annual Meeting
AMG 811 (anti-IFN-gamma) Treatment Leads To a Reduction In The Whole Blood IFN-Signature and Serum CXCL10 In Subjects With Systemic Lupus Erythematosus: Results Of Two Phase I Studies
David A. Martin¹, Andrew Welcher², Michael Boedigheimer², Zahir Amoura³, Alan Kivitz⁴, Jill P. Buyon⁵, Jorge Sanchez-Guerrero⁶, Juanita Romero-Diaz⁷, Alla Rudinskaya⁸, Kevin M. Latinis⁹, S Cohen¹⁰, Cynthia Aranow¹¹, Mike Damore², Winnie Sohn², Kit Chiu², Christine Wang¹², Naren Chirmule², Barbara Sullivan² and James Chung², ¹Medical Sciences, Amgen, Seattle, WA, ²Amgen, Thousand Oaks, CA, ³Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁸Danbury Hospital, Danbury, CT, ⁹Latinis Rheumatology, Leawood, KS, ¹⁰Metroplex Clinical Research Center, Dallas, TX, ¹¹The Feinstein Institute, Manhasset, NY, ¹²Biostatistics, Amgen, Thousand Oaks, CA
Background/Purpose: Interferon-gamma (IFN-g) is a major pro-inflammatory cytokine that modulates the function of several important populations of immune cells including B cells, T cells, and…
Abstract Number: 881 • 2013 ACR/ARHP Annual Meeting
Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus
Nicolas Wisniacki¹, Chris Stebbins², Jadwiga Bienkowska³, Susan Gawlak², Donald Bennett⁴, Yuhong Xiang⁵, Andrea Dearth⁶, Linda C. Burkly⁷, Ann Ranger⁶, Carrie Wager⁵, Laurence S. Magder⁸ and Michelle Petri⁹, ¹Medical Research, Biogen Idec, Maidenhead, United Kingdom, ²Translational Medicine, Biogen Idec, Cambridge, MA, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biostatistics, Biogen idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec Inc, Cambridge, MA, ⁷Biogen Idec, Cambridge, MA, ⁸Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily that signals through its distinct, highly inducible receptor, FGF-inducible molecule 14…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].